Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 8980223)

1.

Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.

Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD.

Cell. 1996 Dec 27;87(7):1161-9.

2.

The renal angiopoietin/Tie2 system in lethal human sepsis.

Aslan A, Jongman RM, Moser J, Stegeman CA, van Goor H, Diepstra A, van den Heuvel MC, Heeringa P, Molema G, Zijlstra JG, van Meurs M.

Crit Care. 2014 Mar 31;18(2):423. doi: 10.1186/cc13806. No abstract available.

3.

Tie2 (to) Abl: Signaling to endothelial cell survival.

Chislock EM, Pendergast AM.

Cell Cycle. 2013 Dec 15;12(24):3709-10. doi: 10.4161/cc.26877. Epub 2013 Oct 21. No abstract available.

4.

Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival.

Chislock EM, Ring C, Pendergast AM.

Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12432-7. doi: 10.1073/pnas.1304188110. Epub 2013 Jul 9.

5.

Mending leaky blood vessels: the angiopoietin-Tie2 pathway in sepsis.

David S, Kümpers P, van Slyke P, Parikh SM.

J Pharmacol Exp Ther. 2013 Apr;345(1):2-6. doi: 10.1124/jpet.112.201061. Epub 2013 Feb 1. Review. Erratum in: J Pharmacol Exp Ther. 2013 May;345(2):329.

6.

Discovery of loperamide as an antagonist of angiopoietin1 and angiopoietin2 by virtual screening.

Gong XW, Mai JH, Xu YH.

Bioorg Med Chem Lett. 2012 Apr 1;22(7):2388-92. doi: 10.1016/j.bmcl.2012.02.036. Epub 2012 Feb 22.

PMID:
22406116
7.

Angiopoietin-1/Tie2 receptor signaling in vascular quiescence and angiogenesis.

Fukuhara S, Sako K, Noda K, Zhang J, Minami M, Mochizuki N.

Histol Histopathol. 2010 Mar;25(3):387-96. Review.

PMID:
20054809
8.

Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects.

Wouters V, Limaye N, Uebelhoer M, Irrthum A, Boon LM, Mulliken JB, Enjolras O, Baselga E, Berg J, Dompmartin A, Ivarsson SA, Kangesu L, Lacassie Y, Murphy J, Teebi AS, Penington A, Rieu P, Vikkula M.

Eur J Hum Genet. 2010 Apr;18(4):414-20. doi: 10.1038/ejhg.2009.193. Epub 2009 Nov 4.

9.

Localization of angiopoietin-1 and Tie2 immunoreactivity in rodent ependyma and adjacent blood vessels suggests functional relationships.

Horton BN, Solanki RB, Rajneesh KF, Kulesza P, Ardelt AA.

J Histochem Cytochem. 2010 Jan;58(1):53-60. doi: 10.1369/jhc.2009.954610. Epub 2009 Sep 28.

10.

Vascular endothelial growth factor activates the Tie family of receptor tyrosine kinases.

Singh H, Milner CS, Aguilar Hernandez MM, Patel N, Brindle NP.

Cell Signal. 2009 Aug;21(8):1346-50. doi: 10.1016/j.cellsig.2009.04.002. Epub 2009 Apr 17.

PMID:
19376222
11.

Tie2 is tied at the cell-cell contacts and to extracellular matrix by angiopoietin-1.

Fukuhara S, Sako K, Noda K, Nagao K, Miura K, Mochizuki N.

Exp Mol Med. 2009 Mar 31;41(3):133-9. doi: 10.3858/emm.2009.41.3.016. Review.

12.

Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations.

Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, Eklund L, Boon LM, Vikkula M.

Nat Genet. 2009 Jan;41(1):118-24. doi: 10.1038/ng.272. Epub 2008 Dec 14.

13.

Regulated proteolytic processing of Tie1 modulates ligand responsiveness of the receptor-tyrosine kinase Tie2.

Marron MB, Singh H, Tahir TA, Kavumkal J, Kim HZ, Koh GY, Brindle NP.

J Biol Chem. 2007 Oct 19;282(42):30509-17. Epub 2007 Aug 29.

14.

Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.

Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, Zonari E, Mazzieri R, Doglioni C, Naldini L.

Blood. 2007 Jun 15;109(12):5276-85. Epub 2007 Feb 27.

15.

Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization.

Bogdanovic E, Nguyen VP, Dumont DJ.

J Cell Sci. 2006 Sep 1;119(Pt 17):3551-60. Epub 2006 Aug 8.

16.

Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells.

Antoine M, Wirz W, Tag CG, Mavituna M, Emans N, Korff T, Stoldt V, Gressner AM, Kiefer P.

Growth Factors. 2005 Jun;23(2):87-95.

PMID:
16019430
17.

Effects of protein and gene transfer of the angiopoietin-1 fibrinogen-like receptor-binding domain on endothelial and vessel organization.

Weber CC, Cai H, Ehrbar M, Kubota H, Martiny-Baron G, Weber W, Djonov V, Weber E, Mallik AS, Fussenegger M, Frei K, Hubbell JA, Zisch AH.

J Biol Chem. 2005 Jun 10;280(23):22445-53. Epub 2005 Mar 21.

18.

Angiopoietin-1 promotes lymphatic sprouting and hyperplasia.

Tammela T, Saaristo A, Lohela M, Morisada T, Tornberg J, Norrmén C, Oike Y, Pajusola K, Thurston G, Suda T, Yla-Herttuala S, Alitalo K.

Blood. 2005 Jun 15;105(12):4642-8. Epub 2005 Mar 3.

19.

Functional inhibition of secreted angiopoietin: a novel role for angiopoietin 1 in coronary vessel patterning.

Ward NL, Van Slyke P, Dumont DJ.

Biochem Biophys Res Commun. 2004 Oct 22;323(3):937-46.

PMID:
15381091
20.

COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity.

Cho CH, Kammerer RA, Lee HJ, Steinmetz MO, Ryu YS, Lee SH, Yasunaga K, Kim KT, Kim I, Choi HH, Kim W, Kim SH, Park SK, Lee GM, Koh GY.

Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5547-52. Epub 2004 Apr 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk